Fig. 2.
Fig. 2. Immunoprecipitation assays of inhibitor plasmas with the A2 and C2 domains. The upper panel shows the results of SDS-PAGE analysis of inhibitor binding to 35S-A2. The patients tested were R7717, R3511, R1911, and R1113 in lanes 1 to 4, respectively. Lane 5 is the negative control without antibody, and lane 6 is the positive control of anti-A2 MoAb 413. In the lower panel depicting 35S-C2 binding, the patient samples and controls are arranged in the same order. The anti-C2 MoAb ESH8 was used as the positive control.

Immunoprecipitation assays of inhibitor plasmas with the A2 and C2 domains. The upper panel shows the results of SDS-PAGE analysis of inhibitor binding to 35S-A2. The patients tested were R7717, R3511, R1911, and R1113 in lanes 1 to 4, respectively. Lane 5 is the negative control without antibody, and lane 6 is the positive control of anti-A2 MoAb 413. In the lower panel depicting 35S-C2 binding, the patient samples and controls are arranged in the same order. The anti-C2 MoAb ESH8 was used as the positive control.

Close Modal

or Create an Account

Close Modal
Close Modal